PHGDH amplifies more quickly in triple-negative breast cancer than in other breast cancer subtypes, and PHGDH is more highly expressed in estrogen receptor-negative tumors than estrogen receptor-positive tumors 33. Here, ESR1 is linked to triple-negative breast carcinoma.